Antimicrobials & Resistance

Antimicrobials

Part 1 of 4 — Selective Toxicity & Cell Wall Inhibitors

The Central Principle: Selective Toxicity

An antibiotic must poison the microbe while sparing the host. Every drug class exploits a structure or pathway that bacteria have and humans lack (or have in a different form):

Vocabulary the MCAT Expects

• Bactericidal drugs kill bacteria (beta-lactams, vancomycin, aminoglycosides, fluoroquinolones); bacteriostatic drugs halt growth and let the immune system finish the job (tetracyclines, macrolides, sulfonamides). Static drugs can suffice in healthy hosts but not in immunocompromised ones.
• MIC (minimum inhibitory concentration): lowest drug concentration preventing visible growth in vitro; MBC is the lowest that kills. In a disk-diffusion test, a larger zone of inhibition around the drug disk means a more susceptible organism.

• The standardized disk-diffusion method is called the Kirby-Bauer test.

• Broad vs narrow spectrum: broad-spectrum drugs hit many species — and devastate normal flora (risk: C. difficile overgrowth).

Beta-Lactams: Suicide Substrates for Transpeptidase

Penicillins, cephalosporins, carbapenems, and monobactams share the strained beta-lactam ring, a structural mimic of the D-Ala-D-Ala terminus of peptidoglycan precursors. Transpeptidases (penicillin-binding proteins, PBPs) attack the ring and become covalently, irreversibly acylated — cross-linking stops. The cell keeps synthesizing wall material and keeps running its autolysins, so osmotic pressure bursts the weakened wall: lysis. Consequences worth reasoning through:

• Bactericidal, but only against actively growing cells building wall
• Useless against organisms without peptidoglycan: Mycoplasma (no wall at all) and intracellular organisms during their wall-less phases
• Gram-negatives are intrinsically tougher targets: the drug must first pass porins in the outer membrane

Vancomycin: Cap the Substrate Instead

Vancomycin is a large glycopeptide that binds the D-Ala-D-Ala terminus itself, sterically blocking both transglycosylation and transpeptidation. Because it acts on the substrate, beta-lactamases cannot touch it — it is the classic drug for MRSA. Too bulky to cross the gram-negative outer membrane, it is essentially a gram-positive-only drug. Resistance (VRE) arises when enterococci swap the terminus to D-Ala-D-lactate, deleting a key hydrogen bond and collapsing binding affinity ~1000-fold.

Selective Toxicity & Wall Inhibitors 🎯

Key Takeaways — Part 1

• Selective toxicity = target what bacteria have and humans lack: wall, 70S ribosome, folate synthesis, gyrase, bacterial RNA pol
• Bactericidal (kill) vs bacteriostatic (halt; immune system finishes) — the difference matters most in immunocompromised hosts
• MIC = lowest concentration preventing growth; broad spectrum = collateral damage to flora (C. diff risk)
• Beta-lactams mimic D-Ala-D-Ala and irreversibly acylate transpeptidases (PBPs); lysis requires ACTIVE growth
• Vancomycin binds the D-Ala-D-Ala substrate itself; gram-positive only; VRE = D-Ala-D-lactate swap
• No wall (Mycoplasma) = intrinsic resistance to all wall-targeting drugs

• Low-yield extras: the standardized disk-diffusion test is the Kirby-Bauer method

Worked Examples — Mechanism Reasoning

Question: A clinician combines penicillin with tetracycline (a bacteriostatic protein-synthesis inhibitor) against a susceptible organism. Predict the interaction.

Solution:

1. Penicillin's killing depends on cells actively building wall during growth.
2. Tetracycline halts protein synthesis and therefore growth.
3. Growth-arrested cells stop making peptidoglycan, so penicillin loses its window — the combination is antagonistic, not additive.

MCAT Strategy: Any time a static drug freezes growth, expect it to blunt a cidal drug whose mechanism requires active division.

Question: Serial two-fold dilutions of drug X (32 down to 0.25 micrograms/mL) are inoculated with equal bacterial suspensions. Tubes at 4 and above stay clear; subculturing the clear 4, 8, and 16 tubes onto drug-free agar yields heavy growth, while the 32 tube yields none. Give the MIC and MBC.

Solution:

1. MIC = lowest concentration with no visible growth = 4 micrograms/mL.
2. MBC = lowest concentration from which organisms cannot be revived = 32 micrograms/mL.
3. MBC far above MIC (here eightfold, three tubes apart; a ratio above about 4 is the usual cutoff) indicates the drug is essentially bacteriostatic at achievable doses — it inhibited but did not kill at 4, 8, and 16.

MCAT Strategy: Clear tube = inhibition; failure to regrow on fresh medium = killing. The MIC/MBC gap operationally defines static vs cidal.

Question: Vancomycin's target, D-Ala-D-Ala, is present in E. coli peptidoglycan, yet the drug fails completely against it. Reconcile.

Solution:

1. E. coli's peptidoglycan sits in the periplasm, behind an outer membrane whose porins admit only small hydrophilic molecules (roughly < 600 Da).
2. Vancomycin is a rigid glycopeptide near 1450 Da — it cannot traverse porins to reach its target.
3. Resistance can thus be a matter of ACCESS, with the target itself perfectly conserved.

MCAT Strategy: Always separate three failure modes: target absent (Mycoplasma vs beta-lactams), target altered (VRE), or target unreachable (gram-negative outer membrane vs vancomycin).

Antimicrobials

Part 2 of 4 — Protein Synthesis Inhibitors: 30S vs 50S

The Selectivity Handle

Bacteria translate on 70S ribosomes (30S + 50S subunits); eukaryotic cytosol uses 80S (40S + 60S). Drugs shaped for the prokaryotic subunits leave cytosolic translation alone — with one caveat the MCAT loves: mitochondrial ribosomes are 70S-like (endosymbiotic ancestry), which explains dose-limiting toxicities such as the hearing loss (ototoxicity) caused by aminoglycosides.

• The same logic covers chloramphenicol's dose-related bone-marrow suppression (distinct from its rare, idiosyncratic aplastic anemia).

30S Drugs ("buy AT 30")

• Tetracyclines chelate divalent cations (do not take with milk or antacids) and deposit in developing teeth and bone.

50S Drugs ("CELLs at 50")

• Clinical tails: clindamycin covers anaerobes above the diaphragm and carries a high C. difficile risk; linezolid is a reserve drug for MRSA/VRE.

Reasoning Anchors

• Peptide bond formation is catalyzed by rRNA, not protein — the ribosome is a ribozyme. Chloramphenicol inhibits an RNA active site.
• Aminoglycosides are the odd class out: protein-synthesis inhibitors are generally static, but misreading actively poisons the cell with junk protein → cidal.
• Aminoglycoside + beta-lactam is classically synergistic: wall damage lets the aminoglycoside flood in.
• Macrolide resistance can come from methylation of the 23S rRNA, which removes the binding site — one methyl group, total resistance. Clindamycin binds an overlapping 50S site, so the same methylation confers cross-resistance to macrolides AND clindamycin.

• The methylase gene is erm, and the macrolide + clindamycin cross-resistance is called the MLS$_B$ phenotype.

Ribosome-Targeting Antibiotics 🎯

Key Takeaways — Part 2

• 70S vs 80S = the selectivity handle; the exception is 70S-like mitochondrial ribosomes (aminoglycoside hearing loss)
• 30S: aminoglycosides (irreversible, misreading, CIDAL, need O$_2$ uptake) and tetracyclines (A-site block, static)
• 50S: chloramphenicol (peptidyl transferase — an rRNA ribozyme), macrolides (exit tunnel/translocation), clindamycin, linezolid (initiation)
• Aminoglycoside + beta-lactam = synergy (wall holes boost uptake); aminoglycosides fail vs anaerobes
• Methylation of 23S rRNA removes the macrolide binding site = target-alteration resistance, with cross-resistance to clindamycin

• Low-yield extras: chloramphenicol's marrow suppression is another mitochondrial-ribosome effect; tetracyclines chelate divalent cations and stain teeth/bone; clindamycin's clinical niche (anaerobes above the diaphragm, C. diff risk) and linezolid's (MRSA/VRE reserve); the 23S methylase gene is erm, and the cross-resistance is the MLS$_B$ phenotype

Worked Examples — Translation Pharmacology

Question: Place tetracycline, chloramphenicol, and erythromycin at their exact steps in one elongation cycle (deliver, bond, move).

Solution:

1. Deliver: aminoacyl-tRNA enters the A site — blocked by tetracycline.
2. Bond: peptidyl transferase (23S rRNA) forms the peptide bond — blocked by chloramphenicol.
3. Move: the ribosome translocates and the chain threads the exit tunnel — blocked by erythromycin.

MCAT Strategy: Learn the cycle, not the drug list — a passage describing a novel inhibitor of translocation should map instantly onto macrolide-like behavior.

Question: In a bacterial in vitro translation system, drug A freezes ribosomes on mRNA as heavy polysomes; drug B causes ribosomes to run off and accumulate as free 70S with truncated peptides released. Match A and B to chloramphenicol vs puromycin (an aminoacyl-tRNA mimic that accepts the chain and dissociates).

Solution:

1. Chloramphenicol blocks bond formation, so ribosomes STALL in place, still clamped to mRNA: drug A (polysomes preserved).
2. Puromycin resembles a charged tRNA, receives the growing chain, then falls off — premature release and ribosome run-off: drug B.
3. Polysome profiles thus distinguish "stall" inhibitors from "release" inhibitors.

MCAT Strategy: Experimental passages test whether you can translate a mechanism into a measurable pattern; stalling preserves polysomes, release collapses them.

Question: A college student has "walking pneumonia" from Mycoplasma pneumoniae. Amoxicillin fails. Why, and what class succeeds?

Solution:

1. Amoxicillin is a beta-lactam; Mycoplasma has no peptidoglycan — the target is absent (Part 1 principle).
2. The organism still translates on 70S ribosomes, so protein-synthesis inhibitors work: a macrolide (azithromycin) or tetracycline is standard.
3. General rule: wall-less and intracellular organisms shift therapy from wall drugs to ribosome or nucleic-acid drugs.

MCAT Strategy: Match the drug's required target to the organism's parts list before considering anything else.

Antimicrobials

Part 3 of 4 — Nucleic Acid, Folate & Membrane Targets

Folate Antagonists: Sequential Blockade

Bacteria must SYNTHESIZE tetrahydrofolate (THF), the one-carbon carrier required for thymidylate and purine synthesis; humans simply eat folate (no synthesis pathway = built-in selectivity).

PABA → (dihydropteroate synthase) → DHF → (dihydrofolate reductase) → THF

• Sulfonamides are PABA structural analogs that competitively inhibit dihydropteroate synthase.
• Trimethoprim inhibits bacterial dihydrofolate reductase (its affinity for the bacterial enzyme vastly exceeds that for the human one — selectivity by DEGREE, not absence).
• Together (TMP-SMX) they block two sequential steps: a synergistic combination that is far harder to defeat with a single mutation. Starved of THF, the cell cannot make dTMP or purines — DNA synthesis halts.

DNA and RNA Machines

• Fluoroquinolones (ciprofloxacin) inhibit DNA gyrase (topoisomerase II) and topoisomerase IV. Gyrase introduces negative supercoils ahead of the replication fork; poisoning it traps the enzyme mid-cut, leaving double-strand breaks — bactericidal. Human type II topoisomerases are structurally distinct.
• Rifampin binds bacterial RNA polymerase, blocking initiation of transcription. Resistance arises fast from single point mutations in the gene for its polymerase binding site — hence rifampin is used in COMBINATION (classically for tuberculosis).

• Rifampin binds the polymerase's beta subunit, encoded by rpoB (the gene where the resistance mutations fall). Trivia: it turns secretions orange.

• Metronidazole is a prodrug: only under the strongly reducing conditions inside anaerobes is its nitro group reduced to a radical that shreds DNA. Aerobes cannot activate it — selectivity via activation chemistry.

• The electron donors that activate metronidazole are the low-potential ferredoxin/flavodoxin systems of anaerobic metabolism.

Membrane Agent: Polymyxins

Polymyxins are cationic detergent-like peptides that bind gram-negative LPS and disrupt both membranes. Because all cell membranes are chemically similar, selectivity is poor — nephrotoxicity limits them to last-resort gram-negative infections.

• Daptomycin inserts into gram-positive membranes, collapsing the membrane potential (it is inactivated by pulmonary surfactant, so never used for pneumonia).

Beyond Bacteria: the Same Logic

Antifungals show the identical design principle with a different handle: fungal membranes use ergosterol where ours use cholesterol. Azoles block ergosterol synthesis; amphotericin B binds ergosterol and punches pores. Narrow chemical differences → usable selectivity, but much less margin than antibacterials (fungi are eukaryotes) — which is why antifungals are systematically more toxic.

Folate, Nucleic Acid & Membrane Drugs 🎯

Key Takeaways — Part 3

• Folate: sulfonamides = PABA mimics (enzyme humans lack); trimethoprim = bacterial DHFR (affinity difference); TMP-SMX = sequential synergy
• Fluoroquinolones trap gyrase/topo IV mid-cleavage → double-strand breaks → cidal
• Rifampin blocks bacterial RNA-pol initiation; one point mutation in its target = resistance → always combination therapy
• Metronidazole = prodrug activated only by anaerobic reduction
• Polymyxins attack membranes — effective but toxic (membranes are universal chemistry)
• Antifungal parallel: ergosterol vs cholesterol = the fungal selectivity handle, with a thinner safety margin

• Low-yield extras: rifampin binds the beta subunit (gene rpoB) and turns secretions orange; metronidazole is activated by ferredoxin/flavodoxin electron donors; daptomycin depolarizes gram-positive membranes and is inactivated by lung surfactant

Worked Examples — Pathway Pharmacology

Question: Bacterial growth inhibited by drug Z is fully rescued by adding thymidine plus purines to the medium, but not by adding PABA. Which pathway does Z block, and where relative to PABA?

Solution:

1. Thymidine + purines are the END PRODUCTS whose synthesis requires THF; supplying them bypasses any folate-pathway block. Z is a folate antagonist.
2. Excess PABA would outcompete a sulfonamide (a competitive PABA analog). No rescue by PABA means the block is DOWNSTREAM of the PABA-using step — consistent with a DHFR inhibitor like trimethoprim.
3. Conclusion: Z inhibits dihydrofolate reductase.

MCAT Strategy: Metabolite-rescue logic: whatever restores growth lies downstream of the block; whatever fails to rescue is upstream or irrelevant.

Question: A gram-negative isolate loses a major porin protein. Predict its susceptibility changes to (a) a small hydrophilic beta-lactam, (b) polymyxin, (c) trimethoprim.

Solution:

1. (a) Beta-lactams reach the periplasm through porins; porin loss reduces entry → resistance rises.
2. (b) Polymyxin attacks LPS on the outer surface directly — no porin needed → unaffected.
3. (c) Trimethoprim is small and lipophilic enough that porin loss has modest effect, though reduced uptake can contribute low-level resistance.
4. Porin mutations are a general PERMEABILITY mechanism — they shift many drugs a little rather than one drug a lot.

MCAT Strategy: For each drug, ask what path it takes to its target; resistance follows the path, not the target, in permeability mutants.

Question: Both amphotericin B (antifungal) and penicillin exploit selective toxicity. Explain the large difference in host toxicity from first principles.

Solution:

1. Penicillin's target (peptidoglycan transpeptidase) has NO human counterpart — selectivity is absolute in principle.
2. Amphotericin binds ergosterol, but cholesterol is chemically similar; partial binding to cholesterol-containing human membranes (notably renal cells) causes pores and nephrotoxicity.
3. Rule: toxicity scales inversely with the chemical distance between microbial and host targets. Bacteria (prokaryotes) offer big distances; fungi (fellow eukaryotes) offer small ones.

MCAT Strategy: When ranking drug safety, compare target divergence: absent target > different enzyme family > similar molecule.

Antimicrobials

Part 4 of 4 — Resistance Mechanisms & MCAT Integration

The Four Ways to Beat a Drug

• Gene names behind the table: PBP2a is encoded by mecA (carried on a mobile cassette); the 23S methylase is erm; rifampin resistance maps to rpoB; tetracycline pumps are encoded by tet genes.

Countermeasures mirror the mechanisms: clavulanate is a suicide inhibitor of beta-lactamase (co-formulated with amoxicillin); methicillin was engineered with a bulky side chain that beta-lactamase cannot attack — and staph answered with a NEW target (PBP2a): an evolutionary arms race in miniature.

Where Resistance Genes Come From — and How They Move

Resistance can arise vertically (spontaneous chromosomal mutation, then selection) or arrive horizontally:

• Conjugation — plasmid transfer through a pilus; R plasmids often carry SEVERAL resistance genes plus the transfer machinery, so one mating event can confer multidrug resistance, even ACROSS species.
• Transduction — a phage mispackages host DNA and injects it elsewhere.
• Transformation — competent cells import naked DNA from lysed neighbors.
• Transposons shuttle resistance genes between plasmids and chromosomes, stacking genes into mobile arrays.

• Integrons are gene-capture platforms that collect resistance gene cassettes in tandem; carried on transposons and plasmids, they build multidrug arrays.

Key conceptual point for the exam: antibiotics do NOT cause the mutations. Resistance variants pre-exist at low frequency; the drug is a selection pressure that lets them take over (the fluctuation test showed mutations arise before, and independently of, exposure: parallel cultures gave wildly variable resistant counts, the "jackpots" of early random mutations).

• The fluctuation test is the Luria-Delbruck experiment (1943), done with phage resistance in E. coli.

Ecology of Resistance

• Selection reservoirs: subtherapeutic dosing, stopped-early courses, and agricultural antibiotic use all enrich resistant subpopulations.
• Normal flora collateral: broad-spectrum therapy clears competitors; resistant organisms (or C. difficile) bloom in the vacancy.
• Biofilms: bacteria in a polysaccharide matrix (catheters, heart valves) grow slowly and are shielded — phenotypic tolerance without any genetic change; devices often must be removed.
• Persisters: dormant cells survive cidal drugs that require active growth, then reseed the infection — again tolerance, not inherited resistance.

The Integration Habit

Every antimicrobial vignette reduces to three questions: (1) What is the drug's target and path to it? (2) Which of the four resistance strategies does the data show? (3) Did the gene move vertically or horizontally? Answer those and the passage answers itself.

Resistance & Integration 🎯

Key Takeaways — Part 4

• Four resistance strategies: destroy (beta-lactamase), alter target (PBP2a, 23S methylation, RNA polymerase mutation, D-Ala-D-lactate), exclude (porins), efflux (pumps)
• Clavulanate = suicide inhibitor of beta-lactamase; MRSA escaped via a NEW target, not a better lactamase
• Drugs select pre-existing mutants; they do not induce mutations (fluctuation test)
• Horizontal spread: conjugation (R plasmids = one-step multidrug resistance, cross-species), transduction, transformation, transposons
• Biofilms and persisters = phenotypic TOLERANCE (no genetic change) — remove the device
• Vignette algorithm: target & path → which of four strategies → vertical or horizontal origin

• Low-yield extras: resistance gene names (mecA for PBP2a, erm, rpoB, tet); integrons capture and stack resistance cassettes; the fluctuation test is the Luria-Delbruck experiment

Worked Examples — Resistance Forensics

Question: A resistant isolate shows: intracellular drug concentration equal to susceptible strains; drug chemically intact after incubation; drug target enzyme purified from the mutant has a 500-fold higher Ki for the drug. Which resistance strategy is this?

Solution:

1. Normal accumulation rules out exclusion and efflux.
2. Intact drug rules out enzymatic destruction.
3. The 500-fold Ki shift localizes resistance to the TARGET: an altered binding site (strategy 2).
4. Sequencing the target gene should reveal the substitution.

MCAT Strategy: The four strategies are experimentally separable: measure drug in, drug intact, and target affinity — each strategy breaks exactly one measurement.

Question: A culture exposed to a cidal drug shows biphasic killing: 99.9 percent die in 4 hours, then a plateau of survivors persists for days. Survivors regrown WITHOUT drug and re-exposed show the identical biphasic curve. Interpret.

Solution:

1. If the plateau were resistant mutants, regrowth would yield a population that survives uniformly on re-exposure. It does not.
2. Identical re-exposure kinetics mean survivors were phenotypic persisters — dormant cells that happened to be non-growing during exposure.
3. Persisters regenerate the same small dormant fraction each generation; genetics are unchanged.

MCAT Strategy: The re-challenge experiment is the discriminator: heritable = resistance; reproducible small fraction = persistence.

Question: A vancomycin-resistance operon first characterized in Enterococcus appears in a clinical S. aureus isolate that also carries a conjugative plasmid. Propose the transfer route and why co-infection sites matter.

Solution:

1. Enterococci and staphylococci co-colonize skin and wounds, providing physical proximity.
2. The resistance operon rides a transposon; during co-infection it can hop onto a conjugative plasmid in Enterococcus, which then transfers to S. aureus by conjugation.
3. Result: VRSA — target alteration (D-Ala-D-lactate) now in a far more virulent host species.
4. Ecologically, heavy vancomycin use (selecting VRE) plus MRSA prevalence set the stage; gene flow follows opportunity.

MCAT Strategy: Horizontal transfer questions want the chain: mobile element → vehicle (plasmid/phage/naked DNA) → mechanism (conjugation/transduction/transformation) → selection pressure that fixes it.